Testing with Cepheid's molecular TB assay can shorten the amount of time suspected patients need to be isolated and save thousands of dollars per patient.
Bruker plans to acquire an 80 percent stake in Hain, which has capabilities in tuberculosis and mycobacteria testing as well as virology and human genetics.
The new plant will serve as the company's hub for launching multiplexed molecular diagnostic kits for tuberculosis and other infectious disease.
The virus emerged in northeastern Brazil and spread southward, though was transmitted through the sylvan cycle, the researchers' analysis showed.
Clinicians identifying and treating S. aureus bloodstream infections reduced the median length of stay by 5.6 days and hospital cost by $13,341 per patient after using Luminex's assay.
The firm plans to make the molecular testing system accessible to low-income countries, in part by reducing costs using reel-to-reel manufacturing.
Plasmodium vivax parasites that infect humans have highly similar genomes to parasites that infect apes, a finding with possible disease-eradication consequences.
The Ann Arbor, Michigan-based firm will compete with a few well-established players offering systems that can run in vitro diagnostic tests as well as lab-developed tests.
The San Diego-based firm's diagnostic system uses spatial thermal cycling and a proprietary liquid metal bath for temperature control for five-minute multiplexed PCR assays.
The test can be used on donated blood samples as well as other human cells and tissues.
The revenue increase was driven by surging direct sales of the firm's diagnostic test cartridges in Europe, the Middle East, and Asia.
Researchers integrated results from a pathogen-host association study with available clinical data to find variants influencing both infection responses and other disease risks.
FIND will lead evaluation studies in Cameroon and Georgia between September 2018 and May 2019 to confirm the assay's diagnostic accuracy and commercial utility.
As part of the agreements, the distributors have committed to purchase a minimum number of Curetis' molecular diagnostic systems over three years.
Clinical research has shown that the assay exhibited 100 percent sensitivity compared to culture-based testing methods, Hologic said.
In addition, Qiagen has partnered with Japan's SRL for companion diagnostic development, and its CareHPV test was added to the WHO list of prequalified IVDs.
Researchers saw subway line-specific microbes on the hands of subway riders, with increased skin microbial community convergence in samples from evening commuters.
Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.
The firm is developing products based in part on DNA-enrichment and bioinformatics technologies developed at Stanford and Harvard, respectively.
The company beat the consensus Wall Street estimate on the top line but missed it on the bottom line. It placed 39 net new ePlex analyzer during the quarter.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.